List view / Grid view
6 March 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...
5 March 2014 | By Biogen Idec
Eisai Co., Ltd. and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease, E2609 and BAN2401...
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...
3 March 2014 | By Roche
Roche announced that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy...
27 February 2014 | By Freddy White, Drug Target Review
Michael Bjerke, Promega's Global Product Manager, Detection, speaks to Freddy White at SLAS 2014.
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
14 February 2014 | By Daiichi Sankyo Company
Norovirus is one of the leading causes of infectious gastroenteritis and the number of infected people reported is increasing both in Japan and globally...
14 February 2014 | By GlaxoSmithKline
GlaxoSmithKline announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, in patients with Eosinophilic Granulomatosis with Polyangiitis...
14 February 2014 | By EBiSC
A consortium of 26 partners has been formed to establish the “European Bank for induced pluripotent Stem Cells” (EBiSC) with support from the IMI.
11 February 2014 | By Merck
MSD and Samsung Bioepis Co., Ltd., announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293...
5 February 2014 | By Pfizer
Agreement to combine MSD’s investigational anti-PD-1 and key Pfizer oncology assets...
5 February 2014 | By Amgen
Amgen and MSD announced that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec...
4 February 2014 | By Domain Therapeutics
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies...
